Keymed Biosciences reports H1 2026 revenue of 617 million RMB, driven by flagship Kangyueda sales

Executive summary: Keymed Biosciences published its first‑half 2026 financial results, showing total revenue of 617 million RMB and highlighting strong performance of its flagship drug Kangyueda. The figures signal growing market acceptance of Keymed’s lead product and provide a concrete basis for valuing the company’s near‑term cash flow prospects.

Who is involved: Keymed Biosciences (HKEX:02162), its executive team, shareholders, and the Kangyueda product development group.

Likely next: The firm will continue to expand Kangyueda’s commercial rollout, anticipate full‑year 2026 guidance in November, and may pursue additional partnership or regulatory milestones in the second half of the year.

Keymed Biosciences announced its interim results for the six months ended 30 June 2026, reporting total revenue of 617 million RMB. The company highlighted that its flagship product, Kangyueda, contributed the majority of this turnover, underscoring commercial progress in its core therapeutic area. The release also included an update on ongoing clinical and regulatory activities, providing investors with a snapshot of operational momentum.

Timeline

2026-08-25 — Keymed Biosciences annonce ses résultats pour le premier semestre 2026 et fait le point sur ses activités (PR Newswire)

Analysis — what this means

Likely next events

Keymed expects to release full‑year 2026 revenue guidance in November 2026.
A potential NDA amendment for Kangyueda’s expanded indication is slated for submission to the China NMPA by Q4 2026.
The company plans a shareholder update meeting on 15 September 2026 to discuss pipeline progress.
Exploratory talks with a multinational pharma partner for co‑development of next‑generation assets are scheduled for H2 2026.

Sectors affected

Biopharmaceuticals
Chinese healthcare
Oncology therapeutics

Regulatory implications

Continued NMPA post‑marketing surveillance obligations for Kangyueda.
Possible requirement for Phase IV safety data if label expansion is pursued.
Compliance with Hong Kong Listing Rules regarding interim financial disclosures.

Historical parallels

Hengrui Medicine’s H1 2020 interim results reported ~500 million RMB revenue, illustrating a similar scale‑up trajectory for a Chinese biotech.
Jiangsu Hengrui’s H1 2019 results showed 420 million RMB revenue, serving as an earlier benchmark for mid‑stage oncology drug commercialization.